Aridis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.78 Insider Own32.77% Shs Outstand15.22M Perf Week-2.75%
Market Cap18.30M Forward P/E- EPS next Y-0.10 Insider Trans0.00% Shs Float14.49M Perf Month-26.39%
Income-46.30M PEG- EPS next Q-0.51 Inst Own11.50% Short Float0.76% Perf Quarter-57.26%
Sales1.50M P/S12.20 EPS this Y-54.70% Inst Trans44.89% Short Ratio0.56 Perf Half Y-63.45%
Book/sh-0.86 P/B- EPS next Y59.50% ROA-226.40% Target Price13.00 Perf Year-83.58%
Cash/sh1.05 P/C1.01 EPS next 5Y- ROE471.40% 52W Range0.88 - 7.72 Perf YTD-54.51%
Dividend- P/FCF- EPS past 5Y-27.30% ROI591.40% 52W High-86.27% Beta0.51
Dividend %- Quick Ratio0.70 Sales past 5Y-7.50% Gross Margin- 52W Low20.45% ATR0.10
Employees34 Current Ratio0.70 Sales Q/Q- Oper. Margin- RSI (14)37.19 Volatility12.59% 8.72%
OptionableYes Debt/Eq- EPS Q/Q1.50% Profit Margin- Rel Volume0.36 Prev Close0.93
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume193.76K Price1.06
Recom2.00 SMA20-10.92% SMA50-26.73% SMA200-58.74% Volume79,415 Change13.61%
Feb-19-20Initiated ROTH Capital Buy $18
May-16-22 05:45PM  
Mar-31-22 06:04PM  
Feb-17-22 11:41AM  
Jan-27-22 06:45AM  
Dec-29-21 06:05AM  
Dec-21-21 02:55PM  
Nov-15-21 10:42AM  
Nov-12-21 04:45AM  
Nov-10-21 08:00AM  
Aug-12-21 09:00AM  
Aug-03-21 03:00PM  
Aug-02-21 08:00AM  
Jul-26-21 08:30AM  
Jul-19-21 08:30AM  
Jul-13-21 12:22PM  
Jul-12-21 04:05PM  
Jun-30-21 04:04AM  
Jun-09-21 09:21AM  
May-11-21 04:01PM  
Mar-30-21 05:49PM  
Mar-26-21 08:00AM  
Mar-08-21 07:30AM  
Feb-23-21 07:25AM  
Feb-16-21 11:56PM  
Nov-24-20 05:30AM  
Nov-20-20 04:05PM  
Oct-27-20 04:24PM  
Oct-19-20 08:30AM  
Oct-14-20 05:30AM  
Sep-08-20 05:30AM  
Sep-04-20 01:32PM  
Aug-11-20 04:05PM  
Jul-15-20 08:42AM  
Jun-26-20 05:30AM  
Jun-22-20 05:30AM  
Jun-18-20 05:30AM  
Jun-15-20 05:30AM  
May-12-20 04:05PM  
May-07-20 12:08PM  
May-04-20 05:30AM  
Apr-29-20 05:30AM  
Apr-15-20 02:28PM  
Apr-08-20 04:59PM  
Mar-06-20 04:05PM  
Mar-05-20 05:30AM  
Mar-04-20 05:30AM  
Feb-28-20 02:15PM  
Feb-18-20 05:30AM  
Jan-28-20 02:56PM  
Jan-17-20 05:34AM  
Jan-03-20 02:44PM  
Jan-02-20 08:46AM  
Nov-13-19 04:05PM  
Oct-19-19 08:47AM  
Oct-11-19 05:30AM  
Sep-30-19 05:30AM  
Sep-27-19 05:45AM  
Sep-08-19 04:28PM  
Sep-03-19 09:18AM  
Aug-14-19 03:40PM  
Aug-12-19 04:05PM  
Jul-31-19 03:01PM  
Jul-30-19 05:30AM  
Jul-19-19 05:30AM  
Jun-27-19 05:30AM  
Jun-10-19 05:30AM  
May-14-19 04:35PM  
Apr-03-19 07:21AM  
Apr-02-19 09:00AM  
Mar-28-19 04:05PM  
Jan-31-19 10:40AM  
Jan-02-19 01:15PM  
Dec-12-18 07:30AM  
Dec-05-18 10:35AM  
Dec-04-18 12:30PM  
Nov-26-18 10:04AM  
Nov-21-18 07:35AM  
Nov-13-18 07:30AM  
Nov-07-18 07:30AM  
Sep-26-18 08:30AM  
Sep-24-18 07:00AM  
Aug-13-18 07:31PM  
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jafri HasanChief Medical OfficerSep 07Buy4.142,0918,6605,100Sep 08 04:05 PM
Jafri HasanChief Medical OfficerSep 03Buy4.153,00912,4873,009Sep 08 04:05 PM
HAMILTON JOHN FDirectorJul 27Buy4.872,0009,7402,000Jul 27 09:37 PM
Truong VuCEOJul 27Buy5.115,00025,550737,353Jul 27 09:36 PM
Patzer EricDirectorJul 27Buy4.845,17525,047702,132Jul 27 09:35 PM